Learn what targeted protein degraders (TPDs) are, how PROTACs harness the ubiquitin–proteasome system to eliminate disease-causing proteins, why degradation can outperform traditional inhibition, and how these therapies are advancing into clinical trials.
Learn what proteolysis-targeting chimeras (PROTACs) are, how they work as small-molecule protein degraders, and why they outperform classic inhibitors by accessing undruggable targets, driving deep protein knockdown, and enabling next-generation cancer therapies like ARV-110.
Learn what PROTACs (proteolysis-targeting chimeras) are, how they work via the ubiquitin–proteasome system, and why protein degraders can outperform traditional small molecule inhibitors in oncology and beyond.
Discover how molecular glues are transforming drug discovery by enabling targeted protein degradation of previously “undruggable” targets. Learn their mechanism, advantages over PROTACs, and emerging AI‑driven design strategies in oncology and immunology.
Learn how targeted protein degradation (TPD) uses PROTACs and molecular glue degraders to hijack the ubiquitin–proteasome system, eliminate disease-causing proteins, and expand the “druggable” proteome beyond traditional small molecule inhibitors.
Learn how targeted protein degraders, especially PROTACs, are transforming small molecule drug discovery by degrading disease‑driving proteins, expanding druggable targets beyond classical enzyme and receptor inhibition.
Discover how next-generation small molecule PROTACs work as “molecular assassins” by harnessing the ubiquitin–proteasome system to degrade disease-driving proteins, overcome drug resistance, and expand drug discovery beyond traditional inhibitors.